vs
Coca-Cola Consolidated, Inc.（COKE）とレスメド（RMD）の財務データ比較。上の社名をクリックして会社を切り替えられます
Coca-Cola Consolidated, Inc.の直近四半期売上が大きい（$1.9B vs $1.4B、レスメドの約1.3倍）。レスメドの純利益率が高く（27.6% vs 7.2%、差は20.4%）。レスメドの前年同期比売上増加率が高い（11.0% vs 9.0%）。レスメドの直近四半期フリーキャッシュフローが多い（$311.2M vs $106.7M）。過去8四半期でCoca-Cola Consolidated, Inc.の売上複合成長率が高い（9.4% vs 9.0%）
コカ・コーラ・コンソリデーテッド社はノースカロライナ州シャーロットに本社を置く、アメリカ合衆国最大の独立系コカ・コーラボトラーです。同社はコカ・コーラ製品の製造・流通・地域販売促進を担当し、米国の飲料供給網において重要な役割を果たしています。
レスメドはオーストラリア発祥の医療機器メーカーで、本社は米国カリフォルニア州サンディエゴに所在します。睡眠時無呼吸症候群や慢性閉塞性肺疾患などの呼吸器疾患治療向けのクラウド接続可能な医療機器を主力製品とし、COVID-19流行下では多数の人工呼吸器を製造提供しました。
COKE vs RMD — 直接比較
損益計算書 — Q4 FY2025 vs Q2 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $1.9B | $1.4B |
| 純利益 | $137.3M | $392.6M |
| 粗利率 | 39.6% | 61.8% |
| 営業利益率 | 12.7% | 34.6% |
| 純利益率 | 7.2% | 27.6% |
| 売上前年比 | 9.0% | 11.0% |
| 純利益前年比 | -23.3% | 13.9% |
| EPS（希薄化後） | — | $2.68 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.9B | $1.4B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.9B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.7B | $1.3B | ||
| Q3 24 | $1.8B | $1.2B | ||
| Q2 24 | $1.8B | $1.2B | ||
| Q1 24 | $1.6B | $1.2B |
| Q4 25 | $137.3M | $392.6M | ||
| Q3 25 | $142.3M | $348.5M | ||
| Q2 25 | $187.4M | $379.7M | ||
| Q1 25 | $103.6M | $365.0M | ||
| Q4 24 | $178.9M | $344.6M | ||
| Q3 24 | $115.6M | $311.4M | ||
| Q2 24 | $172.8M | $292.2M | ||
| Q1 24 | $165.7M | $300.5M |
| Q4 25 | 39.6% | 61.8% | ||
| Q3 25 | 39.6% | 61.5% | ||
| Q2 25 | 40.0% | 60.8% | ||
| Q1 25 | 39.7% | 59.3% | ||
| Q4 24 | 40.0% | 58.6% | ||
| Q3 24 | 39.5% | 58.6% | ||
| Q2 24 | 39.9% | 58.5% | ||
| Q1 24 | 40.2% | 57.9% |
| Q4 25 | 12.7% | 34.6% | ||
| Q3 25 | 13.1% | 33.4% | ||
| Q2 25 | 14.7% | 33.7% | ||
| Q1 25 | 12.0% | 33.0% | ||
| Q4 24 | 12.5% | 32.5% | ||
| Q3 24 | 12.9% | 31.6% | ||
| Q2 24 | 14.4% | 31.2% | ||
| Q1 24 | 13.5% | 31.3% |
| Q4 25 | 7.2% | 27.6% | ||
| Q3 25 | 7.5% | 26.1% | ||
| Q2 25 | 10.1% | 28.2% | ||
| Q1 25 | 6.6% | 28.3% | ||
| Q4 24 | 10.2% | 26.9% | ||
| Q3 24 | 6.5% | 25.4% | ||
| Q2 24 | 9.6% | 23.9% | ||
| Q1 24 | 10.4% | 25.1% |
| Q4 25 | — | $2.68 | ||
| Q3 25 | — | $2.37 | ||
| Q2 25 | — | $2.58 | ||
| Q1 25 | — | $2.48 | ||
| Q4 24 | — | $2.34 | ||
| Q3 24 | — | $2.11 | ||
| Q2 24 | — | $1.97 | ||
| Q1 24 | — | $2.04 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $281.9M | $1.4B |
| 総負債低いほど良い | $2.8B | $403.9M |
| 株主資本純資産 | $-739.7M | $6.3B |
| 総資産 | $4.3B | $8.5B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.06× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $281.9M | $1.4B | ||
| Q3 25 | $1.5B | $1.4B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.2B | $932.7M | ||
| Q4 24 | $1.1B | $521.9M | ||
| Q3 24 | $1.2B | $426.4M | ||
| Q2 24 | $1.7B | $238.4M | ||
| Q1 24 | $401.3M | $237.9M |
| Q4 25 | $2.8B | $403.9M | ||
| Q3 25 | $1.8B | $408.7M | ||
| Q2 25 | $1.8B | $658.4M | ||
| Q1 25 | $1.8B | $663.1M | ||
| Q4 24 | $1.8B | $662.9M | ||
| Q3 24 | $1.8B | $667.6M | ||
| Q2 24 | $1.8B | $697.3M | ||
| Q1 24 | $599.3M | $997.0M |
| Q4 25 | $-739.7M | $6.3B | ||
| Q3 25 | $1.6B | $6.1B | ||
| Q2 25 | $1.6B | $6.0B | ||
| Q1 25 | $1.5B | $5.5B | ||
| Q4 24 | $1.4B | $5.3B | ||
| Q3 24 | $1.3B | $5.2B | ||
| Q2 24 | $1.2B | $4.9B | ||
| Q1 24 | $1.6B | $4.6B |
| Q4 25 | $4.3B | $8.5B | ||
| Q3 25 | $5.7B | $8.3B | ||
| Q2 25 | $5.5B | $8.2B | ||
| Q1 25 | $5.4B | $7.6B | ||
| Q4 24 | $5.3B | $7.1B | ||
| Q3 24 | $5.3B | $7.2B | ||
| Q2 24 | $5.7B | $6.9B | ||
| Q1 24 | $4.3B | $6.8B |
| Q4 25 | — | 0.06× | ||
| Q3 25 | 1.09× | 0.07× | ||
| Q2 25 | 1.10× | 0.11× | ||
| Q1 25 | 1.19× | 0.12× | ||
| Q4 24 | 1.26× | 0.13× | ||
| Q3 24 | 1.39× | 0.13× | ||
| Q2 24 | 1.49× | 0.14× | ||
| Q1 24 | 0.37× | 0.22× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $209.0M | $339.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $106.7M | $311.2M |
| FCFマージンFCF / 売上 | 5.6% | 21.9% |
| 設備投資強度設備投資 / 売上 | 5.4% | 2.0% |
| キャッシュ転換率営業CF / 純利益 | 1.52× | 0.87× |
| 直近12ヶ月FCF直近4四半期 | $619.6M | $1.8B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $209.0M | $339.7M | ||
| Q3 25 | $316.7M | $457.3M | ||
| Q2 25 | $208.1M | $538.8M | ||
| Q1 25 | $198.2M | $578.7M | ||
| Q4 24 | $168.5M | $308.6M | ||
| Q3 24 | $270.8M | $325.5M | ||
| Q2 24 | $242.9M | $440.1M | ||
| Q1 24 | $194.3M | $402.0M |
| Q4 25 | $106.7M | $311.2M | ||
| Q3 25 | $264.1M | $414.4M | ||
| Q2 25 | $148.5M | $508.2M | ||
| Q1 25 | $100.3M | $557.9M | ||
| Q4 24 | $84.8M | $288.0M | ||
| Q3 24 | $142.8M | $307.7M | ||
| Q2 24 | $160.5M | $415.2M | ||
| Q1 24 | $117.2M | $380.8M |
| Q4 25 | 5.6% | 21.9% | ||
| Q3 25 | 14.0% | 31.0% | ||
| Q2 25 | 8.0% | 37.7% | ||
| Q1 25 | 6.3% | 43.2% | ||
| Q4 24 | 4.9% | 22.5% | ||
| Q3 24 | 8.1% | 25.1% | ||
| Q2 24 | 8.9% | 33.9% | ||
| Q1 24 | 7.4% | 31.8% |
| Q4 25 | 5.4% | 2.0% | ||
| Q3 25 | 2.8% | 3.2% | ||
| Q2 25 | 3.2% | 2.3% | ||
| Q1 25 | 6.2% | 1.6% | ||
| Q4 24 | 4.8% | 1.6% | ||
| Q3 24 | 7.2% | 1.5% | ||
| Q2 24 | 4.6% | 2.0% | ||
| Q1 24 | 4.8% | 1.8% |
| Q4 25 | 1.52× | 0.87× | ||
| Q3 25 | 2.22× | 1.31× | ||
| Q2 25 | 1.11× | 1.42× | ||
| Q1 25 | 1.91× | 1.59× | ||
| Q4 24 | 0.94× | 0.90× | ||
| Q3 24 | 2.34× | 1.05× | ||
| Q2 24 | 1.41× | 1.51× | ||
| Q1 24 | 1.17× | 1.34× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
COKE
| Transferred At Point In Time | $1.9B | 99% |
| Transferred Over Time | $15.1M | 1% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
